In contrast, the specific blockade of the IL-6/sIL-6Rα trans-signaling pathway, which is achieved by treatment with sgp130Fc, still allows non-blocked IL-6 to support productive immune responses in defense against bacterial infections. The gene discussed is IL6; the disease is bacterial infectious disease.